MedTrace Logo

A Study to Evaluate the Lipid Regulating Effects of TRIA-662

NCT00758303 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2013-09-13

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness and safety of TRIA-662 (also known as 1-MNA) in treating elevated triglyceride levels in patients not receiving lipid lowering treatment. This study will determine the effects of TRIA-662 on commonly measured blood fats that are known to be important in the prevention of vascular disease.

Conditions

Interventions

DRUG

Low Dose TRIA-662

One Capsule 3 times a day

DRUG

High Dose TRIA-662

3 Capsules 3 times daily

DRUG

Placebo for TRIA-662

Matching Placebo for TRIA-662 taken 3 times a day

Sponsors & Collaborators

  • Cortria Corporation

    lead INDUSTRY

Principal Investigators

  • Jean C Tardif, M.D. · Montreal Heart Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-12-31
Completion
2008-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00758303 on ClinicalTrials.gov